Pharma giant refused costs in HSE tender case
Because of its interest in the outcome, the pharmaceutical giant was joined as a notice party to a Commercial Court action brought by Sanofi against the HSE’s awarding of a tender for the six-in-one vaccine last January
Glaxosmithkline has been refused most of its costs following a legal row in which it said the “safety and efficacy” of one of its vaccines was being challenged by a global rival.
Because of its interest in the outcome, the pharmaceutical giant was joined as a notice party to a Commercial Court action brought by Sanofi against the HSE’s awarding of a tender for the six-in-one vaccine last January.
Glaxo beat Sanofi to ...
